Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

NCT00220194 is registered in ClinicalTrials.gov with San Bernardino Urological Associates Medical Group Inc as lead sponsor.

NCT NCT00220194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00220194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Lead sponsor
San Bernardino Urological Associates Medical Group Inc
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2003
Completion date
June 30, 2005
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of prostate